Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.4746
+0.0076 (1.63%)
At close: Mar 4, 2026, 4:00 PM EST
0.4693
-0.0053 (-1.12%)
After-hours: Mar 4, 2026, 6:44 PM EST
Aditxt Employees
Aditxt had 26 employees as of December 31, 2024. The number of employees decreased by 21 or -44.68% compared to the previous year.
Employees
26
Change (1Y)
-21
Growth (1Y)
-44.68%
Revenue / Employee
$229
Profits / Employee
-$1,624,583
Market Cap
842.90K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 26 | -21 | -44.68% |
| Dec 31, 2023 | 47 | -14 | -22.95% |
| Dec 31, 2022 | 61 | 3 | 5.17% |
| Dec 31, 2021 | 58 | 15 | 34.88% |
| Dec 31, 2020 | 43 | 41 | 2,050.00% |
| Mar 31, 2020 | 2 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyra Therapeutics | 30 |
| Virax Biolabs Group | 19 |
| Biodexa Pharmaceuticals | 13 |
| Azitra | 12 |
| Ensysce Biosciences | 8 |
| CDT Equity | 6 |
| Onconetix | 5 |
| CNS Pharmaceuticals | 5 |
ADTX News
- 3 months ago - Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing - Business Wire
- 4 months ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 - Business Wire
- 4 months ago - Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market - Business Wire
- 4 months ago - Evofem Announces Voting Results from Special Meeting of Stockholders - PRNewsWire
- 6 months ago - Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms - PRNewsWire
- 6 months ago - Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting - PRNewsWire
- 6 months ago - Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Business Wire
- 6 months ago - Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law - PRNewsWire